“Human health care is our goal. We give our first thoughts to patients and their families and helping to increase the benefits health care provides.”
Eisai Inc. is a United States pharmaceutical company based in Woodcliff Lake, New Jersey. Eisai is a subsidiary of the Tokyo human healthcare company Eisai Co., Ltd that focuses on meeting the diverse needs of patients. They are dedicated to providing specialty medications to treat unmet needs in the U.S. to provide relief for patients suffering from a range of medical conditions to improve their quality of life.
Eisai manufactures products for three main medical focuses: neurology, oncology and metabolic diseases.
Eisai Inc. was established in 1981 by Eisai Inc., Ltd, and quickly expanded across the United States. By 1992, Eisai had made an impact across the country, establishing the Eisai Research Institute of Boston in 1987 and the Eisai Corporation of North America in 1992.
They built a pharmaceutical production and formulation research & development facility in Research Triangle Park, North Carolina in 1997, where they would later produce Aricept, Aciphex and other medications
In 2004, they established they moved to Ridgefield, New Jersey, before finding a permanent home in Woodcliff Lake.
- Aricept – Also known donepezil hydrochloride, Aricept is administered for the treatment of dementia caused by Alzheimer’s Disease. It is given to patients with mild, moderate and severe forms of Alzheimer’s Disease, but does not cure the disease. It has been shown to inhibit the breakdown of acetylcholine, a chemical that is crucial for memory, thinking and reasoning.
- Banzel – also known as rufinamide, is a medication used to treat seizures in patients suffering with Lennox-Gastaut Syndrome. Banzel is only used as an add-on to anti-epileptic treatments already being taken by a patient, and is used to reduce seizures that are associated with LGS.
- Fycompa – also known as perampanel, is a medication that aims to reduce seizures and is the only seizure medication that targets AMPA receptors. The medication is believed to attach to these receptors and block glutamate, which carries signals between nerve cells in the brain. The way the drug works is still not fully understood.
Lehigh Center for Clinical Research
Who We Are
Lehigh Center works with companies like Eisai Inc. to share knowledge and understandings of neurological conditions and how to treat them best. We offer clinical trials to treat a range of conditions, including Alzheimer’s Disease, Binge Eating Disorder, Depression and Fibromyalgia.
If you’re interested in participating in one of our trials but don’t see one that you qualify for, you can leave your information and be considered for future study opportunities.